Completed Trials (both are industry trials):

  • Phase 3, double blind, randomized, controlled, study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 mth) in healthy adult female subjects aged 26 years and above (HPV-015) (2009-2014) (NCT00294047) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT00294047.
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (Morab-0003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive-Ovarian Cancer in First Relapse. (2009-2012) (NCT00849667) For more information on the trial, please access the link, https://clinicaltrials.gov/ct2/show/NCT00849667.